Could a common diabetes drug shrink prostate tumors?
NCT ID NCT04887935
First seen Nov 01, 2025 · Last updated May 21, 2026 · Updated 25 times
Summary
This early-phase study tests whether a diabetes medication called dapagliflozin is safe and tolerable when taken for four weeks before prostate removal surgery in men with localized prostate cancer. The study involves 24 participants with intermediate- to high-risk prostate cancer. Researchers will also check if the drug can shrink tumors or cause cancer cell death.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Washington University School of Medicine
RECRUITINGSt Louis, Missouri, 63110, United States
Contact
Contact
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Conditions
Explore the condition pages connected to this study.